Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac 0.4% in Prostaglandin Suppression
NCT00791323Phase 4Completed
- Sponsor
- Allergan
- Start
- Nov 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ketorolac tromethamine in ocular inflammation (2 arms), sponsored by Allergan. Primary endpoint: Mean Prostaglandin E2 Aqueous Humor Levels at Day 3. Started Nov 2008; status: completed.
02
Drugs
ketorolac tromethamine
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT00791323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791323.